Search

Your search keyword '"Valiulis, A."' showing total 148 results

Search Constraints

Start Over You searched for: Author "Valiulis, A." Remove constraint Author: "Valiulis, A." Publisher wiley Remove constraint Publisher: wiley
148 results on '"Valiulis, A."'

Search Results

1. Concurrent validity, cut‐offs and ability to change of patient‐reported outcome measures for rhinitis and asthma in MASK‐air®

2. Relevance of individual bronchial symptoms for asthma diagnosis and control in patients with rhinitis: A MASK‐air study

3. Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air® approach

4. Real‐world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities

5. Mobile health app for monitoring allergic rhinitis and asthma in real life in Lithuanian MASK‐air users

6. Allergen immunotherapy in MASK‐air users in real‐life: Results of a Bayesian mixed‐effects model

7. Available and affordable complementary treatments for COVID‐19: From hypothesis to pilot studies and the need for implementation

9. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

10. Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK‐air®

11. ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy

12. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries?

13. Helsinki by nature: The Nature Step to Respiratory Health

14. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases

15. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

16. Vilnius Declaration on chronic respiratory diseases: multisectoral care pathways embedding guided self-management, mHealth and air pollution in chronic respiratory diseases

17. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

18. European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases: report of the European Union Parliament Summit (29 March 2017)

19. UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan

20. Patient‐centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA‐EAACI approach – ARIA‐EAACI Task Force Report

21. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report

22. Improvement of daily allergy control by sublingual immunotherapy: A MASK ‐air® study

23. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis

24. Rhinitis associated with asthma is distinct from rhinitis alone: The <scp>ARIA‐MeDALL</scp> hypothesis

25. Patient‐centred digital biomarkers for allergic respiratory diseases and asthma: the ARIA‐EAACI approach

26. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air (R) longitudinal study

27. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

28. Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air ® approach

29. Improvement of daily allergy control by sublingual immunotherapy: A <scp>MASK</scp> ‐air® study

30. Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air ® approach

31. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK‐air® longitudinal study

32. Real‐world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities

33. Mobile health app for monitoring allergic rhinitis and asthma in real life in Lithuanian MASK‐air users

34. Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement

35. Comparison of rhinitis treatments using MASK ‐air® data and considering the minimal important difference

36. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

37. Comparison of rhinitis treatments using MASK-air (R) data and considering the minimal important difference

38. Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model

39. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air(R) real-world data

40. SERPINA1 gene polymorphisms in a population‐based ALSPAC cohort

41. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK‐air ® real‐world data

42. Available and affordable complementary treatments for COVID‐19: From hypothesis to pilot studies and the need for implementation

43. Allergen immunotherapy in MASK‐air users in real‐life: Results of a Bayesian mixed‐effects model

44. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air® longitudinal study

45. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air ® real-world data

46. Development and validation of combined symptom‐medication scores for allergic rhinitis*

47. Adherence to treatment in allergic rhinitis using mobile technology : The MASK Study

48. Correction to: Vilnius Declaration on chronic respiratory diseases: multisectoral care pathways embedding guided self-management, mHealth and air pollution in chronic respiratory diseases

49. Management of anaphylaxis due to COVID‐19 vaccines in the elderly

50. Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK‐air®

Catalog

Books, media, physical & digital resources